Vaxart Inc
VXRT
Market Cap$112.9M
Close$
$-0.38
177% downside
Current Fair Value
177% downsideOvervalued by 177% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $112.90 Million |
|---|---|
| Enterprise Value | $183.00 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.03 |
| Beta | 1.15 |
| Outstanding Shares | 227,923,636 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.94 |
|---|---|
| PEG | 5.36 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.86 |
| Enterprise Value to EBIT | -6.7 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.54 |
| Debt to Equity | 2.17 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Vaxart Inc
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped wit...